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ABSTRACT 
          Selenocysteine (Sec; U in one-letter code), the 21st amino acid existing in all 
selenoproteins, has unique biochemical properties due to its selenium atom, including 
a low pKa and a high reactivity with many electrophilic agents. When a selenoprotein 
is translated, the insertion of Sec occurs at a UGA codon, normally yielding 
translational termination. Here UGA can be re-coded as Sec through the presence of a 
species-specific downstream mRNA sequence called Sec insertion sequence (SECIS) 
element. As one of about 25 mammalian selenoproteins, thioredoxin reductase 1 
(TrxR1) contains one Sec residue within its C-terminal tetrapeptide motif, -Gly-Cys-
Sec-Gly-COOH. By utilizing an engineered bacterial SECIS element in the rat TrxR1 
cDNA, we are able to produce recombinant rat TrxR1 with both high yields and 
specific activities, which gives us an international leading edge, as selenoprotein 
production is a common bottleneck for researchers in the field of selenoprotein 
biology. Based on the studies on TrxR1, we have developed a “Sel-tag” for 
recombinant proteins using the C-terminal tetrapeptide motif of TrxR1. We have 
subsequently demonstrated that the selenolate of a reduced Sel-tag provides a “handle” 
which can be utilized for a wide range of selenolate-targeted applications, including a 
one-step protein purification procedure, residue-specific fluorescent labeling and 
radiolabeling with either gamma emitters (75Se) or positron emitting radionuclides 
(11C). 
          We first utilized Sel-tag to investigate the mechanism of antigen presentation 
through carbohydrate based particles (CBP) by tracking the selenium-75 labeled Sel-
tagged Fel d 1, the major cat allergen, in a mouse model. 
          We further applied this technique for studies of apoptosis with a particular 
interest in utilizing Sel-tagged annexin A5 to accomplish multimodality imaging. We 
demonstrate that Sel-tagged annexin A5 labeled either with fluorescent 5-
iodoacetamidofluorescein (5-IAF) or the positron emitter carbon-11 remains functional 
and specifically binds apoptotic cells. This proved to be useful for (i) utilizing 
fluorescently labeled annexin A5 in either the conventional annexin A5 affinity assay 
with flow cytometry or in fluorescent microscopy of cells undergoing cell death, (ii) 
PET imaging of apoptotic liver of health BALB/c mice treated with anti-FAS antibody, 
and (iii) PET imaging of xenograft tumors developed from FaDu cells in SCID mice.  
          We have solved the crystal structure of wild type rat TrxR1 and probed its 
catalytic mechanism. We have shown that the oxidized protein presents a stabilized 
selenenylsulfide motif in cis-configuration, with the Sec residue coordinated to the 
planar surface of a tyrosine side chain (Tyr116), thus located far from the redox active 
moieties of the enzyme proposed to be involved in electron transport to the C-terminal 
motif during catalysis. We believe that Tyr116 plays an important role for catalysis of 
TrxR1, possibly by involvement in electron transfer during the reductive half reaction, 
or by stabilizing the selenenylsulfide configuration of oxidized TrxR1. 
          It has been shown that TrxR1 has pro-oxidant roles especially upon redox cycling 
with certain low molecular weight substrates. Thus we have investigated the potential 
of ROS generation by TrxR1 using wild type enzyme as well as several TrxR1 mutants. 
Utilizing Electron Spin Resonance (ESR) spin trapping with 5-Diethoxyphos-phoryl-5-
methyl-1-pyrroline-N-oxide (DEPMPO), we found that TrxR1 could generate free 
radicals including both hydroxyl radicals (HO˙) and superoxide (O2˙ˉ) upon NADPH 
reduction in the absence of other substrates, and the HO˙ generation was largely 
dependent upon prior enzyme-catalyzed O2˙ˉgeneration, indicating an inherent 
peroxidase activity of TrxR1. Closer analyses revealed that the DEPMPO/HOO˙ adduct 
was a direct substrate of TrxR that could be reduced to DEPMPO/HO˙ in a Sec-
dependent manner.   
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1 INTRODUCTION 
 
1.1 Selenium 
1.1.1 General introduction 
Selenium was discovered in 1817 by Swedish chemists Jöns Jakob Berzelius 
(1779-1848) and Johan Gottlieb Gahn (1745-1818) as a byproduct of sulfuric acid 
production originally from the copper mine in Falun, Sweden. It was originally thought 
to be the element tellurium that had been discovered thirty years previously, which was 
later on proved to be a mistake after careful analysis by Berzelius. Nonetheless, in 
relation to tellurium which was named from the Latin word tellus for “Earth”, Berzelius 
named the new element selenium, from the Greek selene (Σελ νηή ) meaning 
"Moon" 1. 
Selenium is a rare element ranking among the 25 least common elements in the 
earth's crust. The standard atomic mass of selenium is 78.96 and there are six naturally 
occurring isotopes of selenium: 74Se (0.87%), 76Se (9.36%), 77Se (7.63%), 78Se 
(23.78%), 80Se (49.61%) and 82Se (8.73%). The first five are stable isotopes, and 82Se 
has a half life of around 1020 years, which therefore could also be considered as stable 
isotope for practical purpose 2. More than dozens of radioactive isotopes of selenium 
have been characterized. Among them, 75Se is an artificial radioactive selenium isotope 
which has been widely used in the clinic and in research 3; 4; 5; 6; 7, including this thesis. 
 
1.1.2 Selenium in biology 
For a very long time after selenium had been discovered and widely utilized in 
engineering, the major biological property of selenium was considered to be its toxicity. 
Today we know that selenium toxicity is different among individuals and many factors 
could contribute, such as the dose, type of selenium and the exposure time. Symptoms 
of selenium poisoning include significant hair loss, dermatitis, paralysis, muscular 
problems, nausea, fatigue, diarrhea, skin inflammation, etc 8; 9; 10. So far, no proven 
antidote for selenium poisoning has been reported 11. On the other hand, it wasn’t until 
the middle of the last century that selenium was recognized to be essential to life 12; 13. 
Selenium deficiency contributes to several diseases in animals 14; 15; 16, and the first 
human disease shown to be caused by selenium deficiency was Keshan disease 
reported in 1979 17.  
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In mammals, selenium plays an important role in protecting tissues from 
oxidative stress as a component of glutathione peroxidase, which catalyzes the 
reduction of lipid hydroperoxides and free hydrogen peroxide to their corresponding 
alcohols or water, and in thioredoxin reductase, which catalyzes the NADPH-
dependent reduction of  thioredoxin 18; 19. It is also found in the deiodinases, which 
convert thyroxine to triiodothyronine 20. The biologically active form of selenium in 
these enzymes is a naturally occurring amino acid, selenocysteine. 
 
1.2 Selenocysteine 
1.2.1 Chemical properties of selenocysteine 
Chemically, selenium shares a lot of similarities with sulfur, and differs only 
slightly in properties such as in their ionic radius, electronegativity, covalent radius, 
oxidation state etc 21.  
 
Figure 1. Comparison of cysteine and selenocysteine.  
 
Selenocysteine (Sec; U in the one-letter code) is often referred as the 21st 
naturally occurring amino acid 22. As the name suggested, it is structurally similar to 
cysteine (Cys), with an atom of selenium taking the place of the sulfur, forming a 
selenol moiety (Figure 1). Sec has unique biochemical properties due to its selenium 
atom, including a low pKa and a high reactivity with many electrophilic agents 23.  
 
1.2.2 Expansion of genetic code 
The standard genetic code contains 64 codons as shown in most textbooks and 
literature.  61 codons was designated for the common 20 amino acids and 3 codons for 
signaling the termination of protein translation 24. However, more and more studies 
have revealed that certain codons are dual functional, especially the codons designated 
for protein translation termination 25. There are two amino acids, among many others 
than the twenty that are part of the genetic code, that have been discovered to be coded 
genetically: Sec and pyrrolysine (Pyl). Sec is coded by the stop codon UGA (umber) by 
species-specific mechanisms dependent on structural elements of the mRNA (see 
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section 1.3). Pyl is considered to be the 22nd naturally occurring amino acid identified 
only in a few archaea and bacteria, is encoded by UAG, which also serves as stop 
codon (amber) in most organisms 26. It is worthy of mention that in ciliate Euplotes 
crassus, the codon UGA is used for insertion of both Sec and Cys, even within the 
same genes 27. And in mycoplasma species, UGA is used for tryptophan insertion as 
well as termination 28. The codon AUG is also considered to be dual functional, for 
initiating protein translation encoding methionine (Met) in eukaryotes or N-
formylmethionine (fMet) in prokaryotes, and for encoding internal Met within the 
protein 25.  
 
1.3 Selenoprotein 
1.3.1 General introduction 
Selenoprotein exclusively refers to proteins that include one or several 
selenocysteine residues, although there are other selenium modified amino acids such 
as selenomethionine, which may be incorporated into protein through non-genetic 
pathways 29. Selenoproteins are found in all three domains of life. In eukaryote, 
selenoproteins exist almost exclusively in animals. Several selenoproteins have been 
identified in the green alga Chlamydomonas. No selenoproteins have yet been 
indentified in fungi or plants 30. Among bacteria and archaea, selenoproteins seem to be 
less common compared to eukaryotes and only exist in some phylogenetic groups 31.  
In recent years, several bioinformatics studies performed by Gladyshev and 
coworkers have extensively broadened our knowledge about selenoprotein distributions 
in different species 32. There are 25 selenoproteins from human, 24 from rodent 33, at 
least 15 different types of selenoproteins from bacteria and archaea, one single 
selenoprotein (cytosolic thioredoxin reductase) from C. elegans 34; 35. In addition, more 
than 300 different selenoproteins genes were found in samples from the Sargasso Sea 36 
and more than 3600 selenoprotein genes derived from 58 selenoprotein families were 
identified based upon the Global Ocean Sampling (GOS) expedition 37. 
Specifically in E. coli, three selenoproteins have been identified, all of which are 
formate dehydrogenases (FDH) expressed under different conditions. FDHG is 
synthesized in aerobic conditions while FDHF and FDHN are only synthesized in 
anaerobic cells 38. In archaea, a few dehydrogenases and hydrogenases as well as 
glycine reductase were identified as selenoproteins 31; 39. In eukaryote, the types of 
Qing Cheng 
4 
selenoproteins are very different from those in lower organisms with almost no overlap. 
Mammalian selenoproteins will be described in the next section.  
 
1.3.2 Mammalian selenoproteins 
Mammalian selenoproteins can be generally categorized into two groups, one 
group with Sec closely located to the C-terminus, often in the penultimate position.  In 
the other group Sec is located in the N-terminal domain, often in a thioredoxin fold 
with redox activity and functionality 33; 40. The most studied selenoproteins in mammals 
are several types of selenoenzymes that include glutathione peroxidases (GPxs), 
thioredoxin reductases (TrxRs), and iodothyronine deiodinases (DIOs).  
GPx was first discovered in 1957 41 and first identified as a selenoprotein in 1973 
6; 18.  There are five GPxs in humans and four in rodents that are selenoproteins, among 
some other non-selenoprotein GPx family members 33. As mentioned in section 1.1.2, 
GPxs reduce hydroperoxide or free H2O2 to the corresponding alcohol or water, using 
glutathione (GSH) as cofactor, which makes this enzyme an important antioxidant 
enzyme. In the GPx Sec is normally present in its highly reactive deprotonated 
selenolate form (-Seˉ), which can be oxidized by peroxides to selenenic acid (-
SeOOH). The peroxide is therefore reduced to its alcohol form (or water if the substrate 
is H2O2). The selenenic acid in GPx is, however, reduced by two GSH molecules to 
form selenolate again, releasing a glutathione disulfide (GSSG) molecule as the 
byproduct. The oxidized GSSG is subsequently reduced to GSH again by glutathione 
reductase in the presence of NADPH to complete the catalytic cycle. Historically, 
cytosolic GPx (GPx1) was also the first identified mammalian selenoprotein. More 
details about GPxs including different isoforms and enzymatic catalysis as well as the 
function of the enzyme can be found in these references 42; 43; 44; 45. 
 Mammalian TrxRs catalyze the NADPH-dependent reduction of the redox-
active disulfide in thioredoxin (Trx), which serves a wide range of functions in cellular 
proliferation and redox control 46; 47; 48. In addition  to the principle substrate Trx, TrxRs 
react with a broad range of other substrates including low molecular weight disulfide-
containing compounds (e.g. DTNB, lipoamide and lipoic acid), inorganic selenium-
containing compounds (e.g. selenite), organic selenium compounds (e.g. ebselen) and 
some quinones (e.g. juglone) 49; 50; 51; 52. More details about this selenoenzyme will be 
described in section 1.4.3. 
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Mammalian DIOs include three isoforms, DIO1, DIO2, DIO3, which are 
involved in thyroid hormone activation and inactivation 53. DIO1 and DIO2 catalyze 
the conversion of the prohormone, thyroxine (T4), to the active hormone, 3,5,3’-
triiodothyronine (T3). DIO3 comprises the major inactivating pathway that terminates 
the action of T3 and prevents the activation of T4 54. More details about the DIOs are 
given in these references 55; 56; 57.   
It is also noteworthy that selenoprotein P (SELP) is the only known selenoprotein 
containing multiple Sec within one polypeptide. Human SELP contains 10 Sec 
residues, with a longer N-terminal domain containing a single Sec in a redox Trx fold 
and a shorter C-terminal domain containing the remaining 9 Sec residues. SELP’s 
expression, function and role in mammals have recently been reviewed 58; 59.  
Other mammalian selenoproteins include selenophosphate synthetase 2 (SPS2), 
which is a selenoprotein that is also involved in other selenoproteins’ biosynthesis 60, 
and a few selenoproteins whose functions are completely or partially unknown, such as 
selenoprotein H, I, K, M, N, O, R, S, T, V, W and a 15 kDa selenoprotein 33; 61; 62; 63; 64; 
65; 66.  
 
1.4 Thioredoxin system 
1.4.1 General introduction 
The Trx system comprises Trx, TrxR and NADPH and is widely distributed in 
almost all living organisms. The E. coli Trx system was discovered by Peter Reichard 
and coworkers in 1964 as a hydrogen donor for the enzymatic synthesis of 
deoxyribonucleotides by ribonucleotide reductase (RNR) 67. The major difference 
between bacterial and mammalian Trx systems is that mammalian TrxR exists as a 
selenoprotein as mentioned earlier. The Trx system, together with the glutaredoxin 
(Grx) system, plays a vital role in maintaining the redox state of the cell and protecting 
the cell against oxidative stress by catalyzing the reduction of their corresponding 
substrates, especially protein substrates containing a disulfide (Figure 2) 68; 69. 
 
1.4.2 Thioredoxin 
Trx is a 12-kDa oxidoreductase containing a dithiol/disulfide active site. It is 
found in almost all organisms from plant, bacterial, archaea to mammals. Different 
isoforms of Trx are found in most organisms 70; 71; 72; 73. In mammals, two Trx isoforms 
have been identified, namely cytosolic Trx (Trx1) and mitochondrial Trx (Trx2). Both 
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isoforms are essential for mammals 74; 75. Trx belongs to a protein family with a 
common structure termed Trx fold 76. The sequence similarity among Trxs is relatively 
high across different organisms and they share a common active site sequence with two 
vicinal Cys in a CXXC motif 77. Trx’s substrates are broad including ribonucleotide 
reductase, GPx, peroxiredoxin (Prx), insulin, H2O2, GSSG, etc. Insulin is a classic 
substrate used in Trx activity assays 46; 78. 
 
Figure 2.  Redox reactions catalyzed by the Trx and Grx systems. NADPH as the 
electron donor for both systems is mainly produced from the pentose phosphate 
pathway. Both systems share certain common functions, however, their specific roles 
could be different in each organism under different circumstances 48. 
 
1.4.3 Thioredoxin reductase 
TrxRs are dimeric flavoenzymes belonging to the pyridine nucleotide-disulfide 
oxidoreductase family, which is present in all living organisms 79; 80. Two TrxR forms 
have evolved independently and they are mostly distinguished by their sizes of 70kDa 
and 110kDa as dimers. The low-Mr TrxRs are found in lower organisms such as 
bacteria, fungi as well as in plants, while the high-Mr TrxRs are mostly found in higher 
eukaryotes 47. Both types of TrxRs contain one FAD and one redox active disulfide in 
each subunit using NADPH as the co-enzyme. However, the high-Mr TrxRs also have a 
third active site located in each subunit’s C-terminal as a -XCUX or -XCCX motif. The 
TrxRs containing the selenenylsulfide/selenolthiol motif (-XCUX) exist in mammals, 
while those containing the disulfide/dithiol motif (-XCCX) are found in insects such as 
D. melanogaster 81 and A. gambiae 82. In lower eukaryotes such as P. falciparum, the 
third active site exists as a -CXXXXCG motif 83. The catalytic mechanism of these two 
types of TrxR are also different and the high-Mr TrxRs have a much broader substrate 
spectrum mainly, if not all, due to their highly accessible C-terminal active site upon 
reduction.  
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Mammalian TrxR (EC 1.8.1.9) is a ubiquitous NADPH-dependent flavoenzyme 
that has prominent disulfide reductase activity. The cytosolic (TrxR1) and 
mitochondrial (TrxR2) isoforms are the only proteins known to reduce their respective 
Trx substrates (Trx1 and Trx2).  
Mammalian TrxR1 (bovine) was first purified in 1977 84, but it was not until 
1995 that the enzyme was identified as a selenoprotein 19; 85. It is difficult to study the 
use of the Sec residue in a selenoprotein from a structural perspective because of the 
limited supply of pure selenoprotein. Direct purification of native selenoproteins from 
their tissue or organ origins is very laborious due to the low abundance of 
selenoprotein. The barriers of selenoprotein biosynthesis machineries have also made 
structural studies on this unique type of protein difficult. Very few structures of native 
selenoproteins have yet been determined, including only two GPx isoforms purified 
from either bovine erythrocytes 86 or human plasma 87, and rat TrxR1 (Paper IV) 88, 
although several recombinant Sec mutants of different selenoproteins have been used to 
resolve the overall structure of this unique type of proteins 89; 90.  
 
Figure 3. An overall view of native rat TrxR1. This view was built upon the atomic 
coordinates of the oxidized enzyme (PDB code 3EAO) by PyMOL 91, the active sites and 
co-enzyme are indicated by arrows.  
 
The overall structure of mammalian TrxR is exhibited as a NADPH-dependent 
homodimer arranged in a head to tail orientation and each subunit contains three redox-
active sites including one enzyme-bound FAD, one N-terminal -CVNVGC- motif  and 
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one -GCUG motif existing in the very C-terminal of the enzyme (Figure 3). The 
enzymatic reaction catalyzed by mammalian TrxR is intricate with many factors and 
several active sites involved. Upon catalysis, a pair of electrons is transferred from 
NADPH via the FAD to the oxidized N-terminal disulfide to form a reduced dithiol 
motif. It subsequently exchanges the two electrons with the C-terminal selenenylsulfide 
to form a reduced selenolthiol motif 88; 92. The reduced C-terminal selenolthiol is 
essential for the Sec-dependent reduction of oxidized Trx and most of the enzymes’ 
substrates. However the reduction of some substrates, such as certain quinones, is Sec-
independent and it’s believed the N-terminal Cys59/Cys64 dithiol motif is responsible 
for that catalytic activity 93. Figure 4 shows a detailed catalytic cycle of mammalian 
TrxR1. 
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Figure 4. Scheme of mammalian TrxR catalysis. Oxidized enzyme (Eox, species 1) is 
reduced by NADPH to the two-electron reduced enzymes which are equilibrated among 
three different forms (EH2, species 2-4). The charge-transfer complex is indicated by a 
dashed arrow (species 3). The enzyme is further reduced by a second equivalent of 
NADPH to form a four-electron reduced enzyme (EH4, species 5 and 6). The second 
EH4 specie (6), containing a C-terminal selenolthiol motif as well as a charge-transfer 
complex, is believed to be the form of the enzyme normally reducing its substrates. A 
selenenylsulfide (in species 3) is formed subsequently upon catalysis (the oxidative half-
reaction). The Sec-dependent catalysis is thus believed to occur with cycling of species 3 
to 6. When the selenolate of the C terminus becomes exposed in the reduced enzyme, 
this can also be easily derivatized with electrophilic agents (X in the scheme), forming 
enzyme species 7 that is irreversibly inhibited for Sec-dependent reduction of substrates 
such as thioredoxin. However, NADPH can still reduce the FAD moiety to form species 9 
via species 8. The inhibited enzyme species 9 can promote Sec-independent reduction 
of some substrates such as the quinone juglone (Q in the scheme) with high efficiency, 
or at about 5–10% efficiency compared with the native enzyme using DTNB as 
substrate.  
 
Upon reduction of the enzyme, the nucleophilic and highly reactive selenolate 
form of the Sec residue is also prone to attack by electrophilic compounds as 
irreversible inhibitors, including some gold compounds such as auranofin 94, 
aurothioglucose 95, platinum compounds such as cisplatin 96 and oxaliplatin 97, 
nitrosoureas such as BCNU 98, dinitrohalobenzenes 99, arsenic oxide 100 and many 
more.  
 
1.5 Selenoprotein biosynthesis 
The biosynthesis of selenoproteins is a very complex process with many factors 
involved 101; 102; 103; 104. As mentioned earlier, when a selenoprotein is translated, the 
insertion of Sec occurs at a UGA codon, normally resulting in translational termination. 
This expansion of the genetic code is intricate and requires a stem-loop structure in the 
mRNA, which is called the SECIS (Sec Insertion Sequence) element 105; 106. The 
selenoprotein synthesis machinery can be generally divided into two categories. 
Eukaryote and archaea have similar machinery in terms of Sec synthesis and 
subsequent incorporation into selenoprotein. Bacteria have a very different pathway, 
especially in term of the location of SECIS in the selenoprotein mRNA. In bacterial 
selenoprotein mRNA, a SECIS element is situated next to the Sec-encoding UGA 
codon 107; 108. In eukaryotes and archaea, on the other hand, SECIS elements are found 
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in the 3' untranslated region (3'-UTR) of the selenoprotein mRNA, which can direct 
single or multiple UGA codons for Sec insertion (Figure 5) 39; 109. These significant 
differences in the selenoprotein biosynthesis machineries among bacteria, eukaryotes 
and archaea made the conventional techniques of heterologous recombinant protein 
expression in bacteria inapplicable for mammalian selenoprotein for a very long time, 
until the late 1990’s 110; 111. The success in recombinantly expressing mammalian TrxR 
in E. coli is the very foundation of this thesis, which will be described in the following.   
 
Figure 5. Schematic comparison of the SECIS location in bacterial and 
mammalian selenoprotein mRNA.  
 
1.5.1 Selenoprotein expression in bacteria 
The biochemical pathway of Sec synthesis and incorporation in bacteria was first 
elucidated by Böck and coworkers in the late 1980’s 22. Due to its high reactivity, Sec 
does not occur as a free amino acid and as a result there is no Sec pool for selenoprotein 
expression in the cell. Instead, cells use the less reactive selenide (Se2ˉ) as the selenium 
donor, and selenide is converted to selenophosphate by selenophosphate synthetase 
(SelD) 112. Sec synthesis occurs on a dedicated transfer RNA, tRNASec (SelC) 113, which 
is different from standard tRNAs in several aspects. It has a longer extra arm of the 
variable loop, an 8-base pair aminoacyl-acceptor helix compared to the classic 7-base 
pair length, and substitutions at several well-conserved base positions (Figure 6) 114. 
tRNASec is also the sixth serine (Ser) isoacceptor 102.  
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Figure 6. Comparison of E. coli tRNASec and tRNASer 115. 
 
During the biosynthesis of Sec, tRNASec is first charged with Ser by seryl-tRNA 
synthetase (SerS) to form Ser-tRNASec, which is subsequently converted to Sec-
tRNASec by selenocysteine synthase (SelA) using selenophosphate as the selenol group 
donor to replace the hydroxyl group in the tRNASec bound Ser (Figure 7).  
 
Figure 7. Scheme of the Sec biosynthesis in bacteria 
 
Due to structural differences, neither Ser-tRNASec nor Sec-tRNASec is recognized 
by the E. coli elongation factor Tu (EF-Tu) during translation, which avoids unspecific 
Ser insertion into the growing polypeptides. Instead, E. coli has a dedicated elongation 
factor termed SelB for Sec incorporation 116; 117. SelB contains two domains including 
the N-terminal SelB-N and C-terminal SelB-C. The SelB-N is homologous to EF-Tu, 
which specifically recruits Sec-tRNASec and GTP, while the SelB-C binds to the 
bacterial SECIS element. The formation of this quaternary complex of SelB, GTP, Sec-
tRNASec and the SECIS element are required for decoding the UGA from the 
selenoprotein mRNA in bacteria (Figure 8) 102; 106.   
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Figure 8. Quaternary complex for Sec insertion in E. coli. Sec incorporation occurs 
when the UGA codon is positioned at the ribosomal A site. A simultaneous recognition of 
the SECIS mRNA hairpin and the UGA codon by SelB charged with Sec-tRNASec is 
needed. Adapted from Ose (2007) 118. 
 
The machinery of Sec incorporation is highly specific and precise to maintain 
selenoprotein syntheses. All the components involved have to be highly accurate and 
coordinate. For example, SerS must be able to use not only tRNASer but also tRNASec as 
the substrate to provide the precursor for Sec synthesis; the SelA must only convert 
Ser-tRNASec instead of Ser-tRNASer to avoid unspecific Sec insertion at a Ser codon; 
SelB must discriminate Sec-tRNASec from its precursor Ser-tRNASec and reject all 
standard tRNAs while the EF-Tu must reject tRNASec to ensure that Sec is precisely 
inserted at the UGA codon. Furthermore, the balance among SelB, Sec-tRNASec and 
the SECIS element is important for ensuring the formation of the correct quaternary 
complex for Sec incorporation. Most intriguingly, the level of SelB is regulated by a 
SECIS-like segment as a gene expression element on its own mRNA. To conclude, the 
bacterial selenoprotein synthesis is strictly regulated on many levels, including genetic, 
biochemical and physiological. See reference 102 for a complete review on this subject.  
 
1.5.2 Selenoprotein expression in eukaryote 
Although the selenoproteins expressed in eukaryotes and bacteria are almost 
completely independent, the mechanisms for Sec synthesis and incorporation are 
conserved in these two to a certain degree. For example, the biosynthesis of Sec in 
eukaryote also occurs on the dedicated transfer RNA, tRNASec, and uses Ser-tRNASec 
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as the precursor. The Sec incorporation in eukaryotes requires a SECIS element in the 
selenoprotein mRNA as well as a Sec-specific elongation factor. However, recent 
studies have revealed that eukaryotic selenoprotein biosynthesis has evolved to a higher 
level with many more factors and regulators involved 104.   
As mentioned above, the most distinct feature of eukaryotic selenoprotein 
synthesis compared to bacteria is the location of the SECIS element. The fact that the 
eukaryotic SECIS is located in the 3’-UTR in the eukaryotic selenoprotein mRNA has 
several advantages. First, there is no restriction on the amino acid sequence to maintain 
the SECIS stem-loop structure when the SECIS is not in the ORF. Secondly, the 
process of unfolding and refolding the SECIS stem-loop is not needed during the 
translation. Finally, the flexibility of the SECIS as such is much higher, and the 
guidance of multiple Sec insertions from the same mRNA is also allowed 104; 119; 120; 121.   
When Sec is synthesized in the eukaryotes, the Ser moiety on Ser-tRNASec needs 
to be phosphorylated by O-phosphoseryl-tRNASec kinase (PSTK) first, followed by the 
conversion from phosphoseryl-tRNASec to Sec-tRNASec catalyzed by eukaryotic 
selenocysteine synthase (SecS) 122. The selenium donor in eukaryote (and in bacteria) is 
selenophosphate, converted from selenide by selenophosphate synthetase 2 (SPS2) 
using ATP as the co-factor. There is another selenophosphate synthetase 1 (SPS1), 
which has been described in eukaryotes 123. However SPS1 is not required for 
selenoprotein synthesis. Interestingly, SPS2 itself is also a selenoprotein containing an 
active site Sec and is essential for selenoprotein synthesis 60; 124.    
In bacteria, the connection between Sec-tRNASec and SECIS is dependent on a 
solo factor SelB. The corresponding function in eukaryote, however, is achieved by two 
distinct proteins. One is a dedicated Sec-specific elongation factor (eEFSec) that is 
responsible for delivering the Sec-tRNASec to the ribosomal A site for Sec 
incorporation. But, unlike SelB in bacteria, eEFSec is unable to bind the SECIS 
element directly. The recognition of eukaryotic SECIS requires the second factor, i.e. 
SECIS binding protein (SBP2) 125. The interaction between eEFSec and SBP2 is yet to 
be clarified, however it seems that the connection is accomplished by the C-terminal 
domain from both proteins.  
In addition to the aspects mentioned above, there are still very many factors 
involved in this complex biological process of selenoprotein biosynthesis. The 
mechanism has certainly not yet been completely unraveled. More details can be found 
in these reviews 40; 103; 104.   
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1.5.3 Selenoprotein expression in archaea 
As the phylogenetic tree of life suggested, archaea is closer to eukaryote than 
bacteria, which, in a way, could also be substantiated by the fact that the archaea 
selenoprotein synthesis machinery is very similar to that of eukaryote. The SECIS 
element of the archaea selenoprotein mRNA is located in the mRNA’s 3’-UTR. A 
specific elongation factor (aSelB) is employed to recognize Sec-tRNASec and deliver 
the Sec into the growing polypeptide 31; 39. However, aSelB is unable to directly bind 
the SECIS element, indicating that another protein, like SBP2 in eukaryote, is involved 
in the connection between SECIS and aSelB, although this protein remains unknown 39.   
 
1.5.4 Recombinant selenoprotein production in E. coli 
The heterologous expression of recombinant protein, especially in E. coli, has 
been vastly developed and utilized in almost every aspect of life science since the 
recombinant DNA technique was invented some 40 years ago. Yet, for a very long 
time, the unique species-specific selenoprotein synthesis machinery has hindered the 
development of recombinant selenoprotein productions using conventional 
recombinant technology. In the late 1990’s however, Arnér and coworkers had 
developed a unique methodology for recombinant selenoprotein production and 
successfully implemented heterologous expression of mammalian TrxR in E. coli 110, 
which has provided a lot of possibilities in the selenoprotein research field.  
As previously mentioned, the SECIS element in bacterial selenoprotein mRNA is 
situated next to the Sec-encoding UGA codon, while mammalian SECIS element is 
located in the 3’-UTR of the selenoprotein mRNA. This difference makes direct 
expression of mammalian selenoprotein in E. coli, without altering the wild type amino 
acid sequence, impossible. However, due to the fact that the Sec of mammalian TrxR1 
is penultimately positioned at the very C-terminus of the protein, Arnér and coworkers 
were able to equip TrxR1 ORF with a bacterial type SECIS element next to the UGA 
codon without interfering with the coding region of TrxR1, and consequently achieved 
the heterologous expression of the native rat TrxR1 in E. coli. In this study, a modified 
E. coli FDH-H SECIS element was utilized to meet the requirement for the rat TrxR1 
sequence as well as the binding site recognized by E. coli SelB. Subsequently, an 
assistant plasmid termed pSUABC harboring three sel genes (selA, selB and selC) 
essential for E. coli selenoprotein synthesis constructed in August Böck’s lab was 
introduced into this novel selenoprotein synthesis construct 126, which had increased the 
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efficacy of selenoprotein production 110; 111; 127; 128. Using rat TrxR1 as a model for 
selenoprotein production, Rengby and coworkers further optimized the expression 
conditions to yield about 40 mg rat TrxR1 with a specific activity of 15-25 U/mg from 
one liter bacterial culture 129. The specific activity can be increased to 40-60 U/mg by 
affinity chromatography utilizing an in-house affinity column named phenylarsine 
oxide (PAO) sepharose (see section 2.2.3) 88; 130. 
The limit of this methodology is that only a few types of natural selenoproteins, 
mainly mammalian TrxRs, have been expressed. The inherent barrier of the bacterial 
selenoprotein biosynthesis machinery is still difficult to utilize in other natural 
selenoprotein expressions, especially for the selenoproteins containing internal or 
multiple Sec residues.  
  
1.5.5 Development of the Sel-tag 
As mentioned previously, mammalian TrxR1 is a selenoprotein containing a Sec 
residue within the C-terminal tetrapeptide -Gly-Cys-Sec-Gly-COOH, which is essential 
for the catalytic activity acting as redox active site. Inspired by the success of 
heterologous expression of rat TrxR1 in E. coli, a Sel-tag concept was developed for 
recombinant proteins, mimicking the C-terminal motif of TrxR1 127. The Sel-tag can be 
coupled to recombinant proteins expressed in E. coli and used for novel biochemical 
and biomedical applications. To summarize, the Sel-tag is a redox active motif whose 
reactivity can be “released” under controlled conditions by reduction with DL-
dithiothreitol (DTT) or other reductants. The selenolate of the reduced Sel-tag provides 
a “handle” that can be utilized for selenium based applications, including a one-step 
purification procedure based upon the affinity binding to PAO sepharose and residue-
specific selenolate-targeted protein labeling with either fluorescent or radioactive 
ligands. In its oxidized state, however, the selenenylsulfide of the Sel-tag is inert and 
thereby protects the reactive Sec residue from unspecific reactions with electrophilic 
compounds 127; 128; 131.   
 
1.6 Molecular imaging 
1.6.1 General introduction 
An official definition of molecular imaging has been adopted by the Society of 
Nuclear Medicine (SNM) and its Molecular Imaging Center of Excellence (MICoE). It 
reads: “Molecular imaging is the visualization, characterization, and measurement of 
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biological processes at the molecular and cellular levels in humans and other living 
systems.” 132; 133 Molecular imaging is a broad field that encompasses many techniques, 
with potential applications ranging from bench to clinical research and has been 
especially used in oncological, neurological, psychiatric and cardiovascular disciplines. 
Apart from its obvious diagnostic capability, this technique has been contributing more 
and more to therapeutic monitoring in recent years by evaluating or optimizing new 
drugs in both pre-clinical and clinical trials.   
Molecular imaging utilizes the chemical interactions of so-called biomarkers, 
also known as probes or tracers, to visualize particular targets or pathways in a given 
area of interest. This is very different from other techniques such as X-radiation 
imaging (X-ray), computed tomography (CT) and magnetic resonance tomography 
(MRT) which primarily show body structure by detecting the differences in quantities 
or contrasts such as density or water content.  
Among the many different types of biomarkers that have been used in functional 
imaging, protein-based probes would be ideal for developing molecular imaging 
techniques based on the specific binding of proteins to unique cell surface receptors, 
antibody-like binding to specific antigens, and many more. Although proteins possess a 
high capacity and specificity in target binding, they have yet to be widely used as 
probes for functional in vivo imaging due to the lack of efficient labeling procedures. 
The innovative Sel-tag technology, however, presents a novel strategy for addressing 
this dilemma. Through its chemical features, the Sel-tag can be used to achieve specific 
and residue-selective protein labeling with either fluorescent or radioactive 
electrophiles and the products can subsequently be used as efficient protein probes for 
functional molecular imaging. Applications in a few such research areas will be briefly 
discussed in the following sub-sections.  
 
1.6.2 Protein fluorescent labeling 
Fluorescent labeling can be generally summarized as a process of covalently or 
non-covalently coupling a fluorophore to another molecule, mostly a protein or nucleic 
acid. In most cases, fluorescent labeling of a protein is accomplished by covalently 
binding  amine- or thiol-groups of the side chains of lysine or cysteine residues with a 
reactive fluorophore. Fluorescein is one of the most common fluorophores used in life 
science 134. Others include rhodamine, cyanine, coumarin, etc. and new generations 
with better biochemical properties are continuously being developed. These 
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fluorophores are normally conjugated with a reactive group in order to achieve specific 
labeling of the amine- and thiol-groups. Common reactive groups include amine-
reactive isothiocyanate or succinimidyl esters, and thiol-reactive maleimide or 
iodoacetamide. A few commonly used fluorescein derivatives are shown in Figure 9. 
These fluorescent compounds are widely used for labeling antibodies and other protein-
based probes for use in fluorescence microscopy, flow cytometry and 
immunofluorescence-based assays such as western blotting and enzyme-linked 
immunosorbent assay (ELISA). 
A protein can also be fluorescently labeled by the recombinant introduction of a 
self-fluorescent protein as a fusion tag. The most commonly used is green fluorescent 
protein (GFP) of the jellyfish Aequorea victoria 135. As of today, many new GFP 
derivatives have been engineered that exhibit different biochemical and physical 
properties, such as brightness, excitation and emission spectra, photostability, pH 
resistance, etc. For an in-depth review of these types of proteins and their applications 
in molecular imaging, see references 136; 137. 
 
Figure 9. Fluorescein derivatives. Fluorescein isothiocyanate (FITC) and NHS-
fluorescein are amine-reactive derivatives of the fluorescein dyes, while fluorescein-5-
maleimide and 5-Iodoacetamidofluorescein (5-IAF) are thiol-reactive. 
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In this thesis, thiol-reactive fluorescent compounds such as 5-IAF are utilized in 
Sel-tagged protein fluorescent labeling. As mentioned previously, the reduced 
selenolate form of Sec in the Sel-tag is much more reactive than a Cys residue and this  
feature enables rapid specific Sec-targeted protein labeling in the presence of an excess 
amount of DTT 127; 128.  
 
1.6.3 Protein radiolabeling 
Similar to fluorescent labeling, proteins can also be radiolabeled and these 
radiolabeled proteins are becoming increasingly important in a variety of pre-clinical 
and clinical investigation.  
Sulfur-35 and iodine-125 or iodine-131 are the radionuclides that have mostly 
commonly been used for direct peptide or protein radiolabeling.  Sulfur-35 decays into 
chlorine-35 by beta emission. Metabolic labeling of proteins with [35S]-Met or [35S]-
Cys has been widely used to study protein synthesis, processing, and primary 
sequences 138. Sulfur-35-labeled agents targeting the primary amino group of lysine 
residues have also been used for radiolabeling proteins 139.  
Iodine-125 decays into tellurium-125 by electron capture, producing gamma rays, 
while iodine-131 decays into xenon-131 with beta and gamma emissions. Both 
radionuclides can be incorporated into peptide or protein by the mean of direct 
radioiodination 140. 125/131Iˉ is converted to the reactive species of 125/131I2 or 125/131I+ by 
oxidizing agents and the reactive species can substitute into the tyrosine residues of the 
protein or into other residues such as histidine and tryptophan in certain circumstances 
141.  
In the selenoprotein research field, as well as in this thesis, selenium-75 has been 
routinely used to detect the incorporation of Sec. This will be discussed in more detail 
in section 2.2.4. 
Some of the radionuclides used for functional in vivo molecular imaging 
applications such as single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) are listed in Table 1.  The SPECT nuclides have 
been used more than PET nuclides for protein labeling, though widely efficient and 
specific methods are still lacking. 
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Table 1. Radionuclides used for PET/SPECT imaging 
Radionuclide T½ Emission Modality Examples of clinically  used tracers Ref 
  15O  2.03 min   β+   PET 15O-H2O 142 
  13N  9.97 min   β+   PET 13N-N2, 13N-ammonia 143; 144 
  11C  20.38 min   β+   PET 11C-choline, 11C-methionine 145; 146 
  68Ga  67.71 min   β+, γ   PET 68Ga-DOTATOC 147 
  18F  109.7 min   β+   PET 18FDG, 18FES 133; 148 
  64Cu  12.7 hr   β+, γ   PET 64Cu-ATSM 149 
  76Br  16.2 hr   β+, γ   PET 76Br-MIBG 150 
  124I  4.18 days   β+, γ   PET 124I-cG250 151 
  99mTc  6 hr   γ   SPECT 99mTc-Anx A5, 99mTc- sestamibi 152; 153 
  123I  13.3 hr   γ   SPECT 123I-FP-CIT 154 
  111In  2.8 days   γ   SPECT 111In-DTPA trastuzumab 155 
  67Ga  3.3 days   γ   SPECT  67Ga-citrate 156 
 
1.6.4 Positron Emission Tomography 
PET is a non-invasive nuclear medicine imaging technique, which produces 3D 
images of functional processes in the body as traced by molecules labeled with positron 
emitting radionuclides (Table 1). In the radioactive decay, a positron is emitted, it 
travels a few millimeters (depending on the media and positron energy), slows down 
eventually to collide with an electron and they annihilate each other to produce energy 
in the form of two anti-parallel 511 keV gamma-rays. Hence it is possible to localize 
their source along a straight line of coincidence when the gamma-rays are captured by 
two detectors in a PET camera ring 157. The most commonly used positron emitting 
nuclides include 15O, 13N, 11C and 18F, while others such as 64Cu, 124I, 76Br, 82Rb and 
68Ga are used, but less often 158.  By varying the tracer molecules, PET imaging is used 
in many basic and clinical research areas, for example, cell proliferation can be 
observed by targeting DNA replication using positron-emitting thymidine analogues as 
the tracers 159; bone remodeling can be studied using [18F]fluoride ion 160; tumor 
perfusion can be estimated using [15O]H2O 161.  
Currently the positron emitting tracer most widely used clinically is 
[18F]fluorodeoxyglucose (FDG) 162. It is a D-glucose analog in which the 2-hydroxyl 
group has been replaced by a 18F (figure 10). After the injection into the blood stream, 
FDG can be specifically transported into cells by glucose transporters and subsequently 
enter the first step of glycolysis. FDG is phosphorylated to FDG-6-phosphate by 
hexokinase, but the product cannot serve as a substrate for the next step in glycolysis 
due to the lack of 2-hydroxyl group. As a result, FDG-6-phosphate accumulates in the 
cell. Therefore, FDG is acting as a tracer predominantly targeting glucose transporters 
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and/or hexokinase, which means higher metabolic demands for glucose will be result in 
higher FDG accumulation. FDG/PET is often used in cancer diagnoses because many 
types of cancer cells have increased glucose metabolism. The accumulation of FDG in 
cancer cells may therefore be higher than in “background” tissues, which allows their 
localization. However, FDG uptake is neither selective nor specific for cancer cells. 
FDG/PET is also regularly used to assess alterations of glucose metabolism in the 
brain, in cardiovascular diseases, Alzheimer’s disease and other central nervous system 
disorders, infections, autoimmune and inflammatory diseases 163; 164; 165; 166; 167. 
 
Figure 10. Comparison of D-glucose and [18F]FDG.  
 
Dedicated small-animal PET cameras have been becoming more widely available 
in recent years allowing the use of rodents and rabbits 168 as experimental subjects, 
which can greatly facilitate the development of molecular imaging assays prior to 
human tests. The spatial resolution of these dedicated animal scanners is higher than 
that of clinical scanners (1~2 mm vs 3~8 mm, respectively). However, small animals 
can only be injected with correspondingly small masses of tracer molecules, which 
therefore requires high specific radioactivity of the tracers used in small animal 
imaging 158.  
The lack of anatomical information in PET imaging has recently been 
compensated by combining it with other morphology-based techniques, such as CT and 
MRI. PET/CT systems are already the clinical routine worldwide, since the information 
obtained simultaneously from both modalities significantly improves diagnoses and 
decision making 169; 170. PET/MRI, however, is still at the prototype level, continuously 
undergoing development and refinement 171. Future technical advances are expected to 
narrow the current gap between the PET component of PET/MRI devices and stand-
alone PET scanners as well as the PET component form PET/CT system in terms of 
sensitivity and spatial resolution 172.  
In summary, the development and improvement of PET technologies as well as 
novel tracers will be important for taking full advantage of the high sensitivity and 
efficacy of PET as a diagnostic imaging modality.  
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2 PRESENT INVESTIGATION 
2.1 Aims of this thesis 
This thesis has two major focuses both centered on studies on mammalian TrxR. 
First, inspired from our successful heterologous expression of rat TrxR1 in E. coli, we 
have developed the concept of Sel-tag by mimicking the C-terminal redox active 
tetrapeptide motif of TrxR1, which could be coupled to recombinant protein expressed 
in E. coli for novel applications in both biochemistry and biomedicine. Secondly, 
bearing its natural “Sel-tag”, recombinant rat TrxR1 can be further purified over an in-
house PAO sepharose to greatly enrich the Sec containing form (i.e the active enzyme), 
which allows us to crystallize this wild type selenoenzyme and solve the structure and 
in-depth studies of enzymatic kinetics on TrxR1 and its mutants were subsequently 
performed.  More specifically, the aims for each of the papers are as followed: 
 
Paper I: In this study, we characterized the necessity of Sec for the Sel-tag 
reactivity and evaluated the Sel-tag based purification and fluorescent- or 
radiolabeling of recombinant proteins produced in E. coli.  
 
Paper II: 
 
 
 
 
In this study, we utilized Sel-tag in an in vivo system to investigate the 
mechanism of antigen presentation by carbohydrate based particles 
(CBP). This was achieved by tracking the selenium-75 labeled Sel-tagged 
Fel d 1, the major cat allergen, in a mouse model. 
 
Paper III: In this study, we evaluated the potential of a Sel-tag in functional imaging 
by multimodality imaging of apoptosis through the Sel-tagged annexin 
A5 utilized in both fluorescent based optical imaging and PET imaging. 
 
Paper IV: 
 
In this study, we crystallized wild type rat TrxR1 and solved the structure. 
The structural information about Sec and its interaction with its 
surrounding environment, together with the studies on several rat TrxR1 
mutants, gave us a better understanding of the catalysis of this enzyme.  
 
Paper V: In this study, we have observed an unusual phenomenon that TrxR1, 
normally serving as an antioxidant enzyme, is able to catalyze a 
significant production of superoxide through an inherent oxidase activity. 
Some of the superoxide may subsequently be converted to free hydroxyl 
radicals. This study was mainly accomplished through electron spin 
resonance (ESR) using wild type rat TrxR1 and several mutants. 
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2.2 Comments on methodology 
The methods used in Papers I-V can be found in the “Material and Methods” 
sections from each paper respectively. In addition, the methods related to Sel-tag 
technology can also be found in the paper included in this thesis as the Appendix, 
which includes: 
 Principles of the design and construction of a Sel-tagged protein 
 Production of PAO sepharose  
 Sel-tagged protein purification through the PAO sepharose  
 In situ selenium-75 labeling of the Sel-tagged protein 
 Sec-specific fluorescence labeling 
 Sec-specific labeling with a positron emitting electrophile  
A few comments of the methodologies utilized in this thesis will be briefly 
described in the following text, as they may be of interest for some readers of this 
thesis. 
 
2.2.1 Recombinant selenoprotein production in E. coli 
As mentioned earlier, the method we used for selenoprotein production in E. coli 
is only suitable for the selenoproteins whose Sec is incorporated in the C-terminal 
region if any amino acid sequence translated from bacterial SECIS is not supposed to 
be introduced. There are several unique features about the bacterial FDH-F SECIS 
element we have used in the thesis. It contains an invariable loop region that binds the 
Sec-specific SelB elongation factor and it has to be positioned 11 nucleotides (nt) 
downstream from the Sec-encoding UGA codon (see section 1.3.3). When these 
requirements are fulfilled, the Sec residue can thereby be introduced into the protein 
located from the ultimate to preantepenultimate position in the protein (Figure 11).   
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Figure 11. Potential position of Sec in the recombinant selenoprotein produced 
in E. coli. The UGA codon has to be positioned 11 nt upstream of the invariable 
sequence of the FDH-F SECIS element. The real stop codon is indicated by the arrow. 
Translated sequences of the Sec-containing protein C-terminal are on the right. 
 
2.2.2 Application of Sel-tag 
To our knowledge, no other protein probes have been reported that are as 
versatile as the Sel-tag utilizations in biotechnological applications in terms of specific 
protein purification and protein labeling. However the application of Sel-tag does 
require a few prerequisites for the protein of interest to be Sel-tagged. First of all, it 
must be possible to produce the target protein in E. coli. Secondly, the function or 
activity of the target protein must not rely on its carboxy-terminal since the Sel-tag can 
only be introduced at the C-terminus of the protein. Finally, the target protein must 
tolerate reduction with DTT or other equivalent reductants if the reactive selenolate 
form of Sec is needed for the downstream application. However for applications such 
as those utilizing selenium-75 labeled proteins, DTT is not necessarily a concern. 
 
2.2.3 Protein purification through PAO sepharose 
PAO sepharose was originally developed for purification of proteins containing 
vicinal dithiols 173; 174. We reasoned that the Sel-tag should also have a high affinity, if 
not better, toward PAO sepharose, which was proved to be correct (Figure 12) 127; 128; 
131. This affinity could be further substantiated by the fact that PAO is an efficient 
inhibitor of mammalian TrxR1 specifically targeting the enzyme’s C-terminal active 
site 100.  
 
Figure 12. Schematic illustration of the affinity between PAO sepharose and Sel-
tagged protein including mammalian TrxR. To bind to PAO sepharose, the Sel-tag 
motif needs to be reduced by DTT. Eventually the covalently bound protein can be eluted 
by DMPS (2,3-dimercapto-1-propanesulfonic acid, sodium salt) 128. 
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There was an affinity chromatography product using the same principle called 
ThioBond that was commercially available from Invitrogen. However, it was 
discontinued.  As a result, we synthesize PAO sepharose ourselves nowadays for our 
TrxR or Sel-tagged protein purification. The principle of making PAO sepharose is to 
couple p-aminophenylarsine oxide (PAPAO) to the sepharose harboring pre-activated 
carboxyl group, so the primary amine group from PAPAO is covalently attached to the 
carboxyl group by forming a peptide bond. Both precursors are available from different 
vendors, however, we also synthesize PAPAO ourselves using a method previously 
described 175.   
 
2.2.4 In situ selenium-75 protein labeling  
Selenium-75 labeling is an easy method for detecting selenoproteins. In our lab, 
this method was routinely used to confirm the integrity of the recombinant 
selenoprotein expression system that has been constructed. To achieve this, [75Se]-
selenite is added to the selenoprotein expression bacterial culture to enable the de novo 
synthesis of [75Se]-Sec using [75Se]-selenite as the selenium source. Consequently, the 
[75Se]-Sec will be incorporated into the nascent selenoprotein given all conditions and 
components for selenoprotein production are provided (see section 1.3.3). In addition to 
[75Se]-selenite (0.5-1 µCi/mL bacterial culture), we normally add an additional 5 µM 
normal selenite into the culture to ensure a sufficient selenium supply. For studies 
requiring a higher specific activity [75Se]-labeled protein such as [75Se]-Fel d 1 used in 
Paper II, more [75Se]-selenite up to 15 µCi/mL could be added 176; 177. 
Another important issue in increasing the efficiency of Sec incorporation is the 
timing of the selenoprotein expression induction. Rengby and coworkers found it is 
favorable to add IPTG into the bacterial culture at its late exponential phase. The so- 
called “24, 24, 2.4” protocol 129 is utilized throughout this thesis in the production of rat 
TrxR1 as well as all other Sel-tagged proteins.  
 
2.2.5 Selenolate-targeted protein labeling 
Most, if not all, thiol-reactive reagents are expected to have a higher affinity to a 
selenolate. However, they are called thiol-reactive reagents for a reason. When Sel-tag 
is utilized for protein labeling, we should always keep in mind that if there is a Cys 
residue in the protein that is vital to the function of the protein, it should not be 
targeted. We minimize the risk of Cys-targeting by three measures, namely using lower 
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pH, short time, and excessive DTT upon protein labeling through Sel-tag. We normally 
label Sel-tagged protein with electrophilic compounds, such as 5-IAF and Alexa488-
meilamide in PBS (phosphate buffered saline, pH 7.4) or TE buffer (50 mM Tris-HCl, 
2 mM EDTA, pH 7.5). Sec is more reactive than Cys due to the fact that the selenol 
group is mostly deprotonated at physiological pH while the thiol group is mostly 
protonated due to the different pKa values (5.2 for Sec, 8.3 for Cys). The reaction is 
normally very rapid, lasting for 20 minutes, and is terminated with desalting (e.g NAP-
5 column), which efficiently minimizes Cys targeting. Quick labeling is also a 
prominent advantage of Sel-tag when short-lived positron emitting electrophiles such as 
[11C]methyl iodide are used for labeling. Last but not least, during Sel-tag labeling, we 
normally have 10-20 fold molar excess of DTT compared to the target protein, which 
could also protect any structural Cys from unwanted alkylation. 
 
2.2.6 Endotoxin contamination 
This thesis is largely dependent on recombinant protein production in E. coli. 
Therefore the endotoxin contamination in the protein preparation must be taken into 
consideration when in vivo imaging is performed utilizing these protein samples.  
 
Figure 13. Schematic structure of E. coli LPS. Gal, galactose; NGa, N-acetyl-
galactosamine; NGC, N-acetyl-glucosamine; Gln, Glucosamine. Adapted from 
Magalhaes (2007) 178. 
 
Endotoxin is mainly related with Gram negative bacteria such as E. coli and it 
almost exclusively refers to lipopolysaccharides (LPS, Figure 13), which consists of a 
polysaccharide chain and a lipid moiety (lipid A) 179; 180. Generally, the toxicity of LPS 
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is associated with lipid A while the immunogenicity is associated with the 
polysaccharide components. Being temperature and pH stable molecules, the removal 
of endotoxins from labile biomolecules, such as proteins, is very challenging. The most 
common methods for endotoxins removal are ultrafiltration and ion exchange 
chromatography. Endotoxins are approximately 10 kDa in size but can form large 
aggregates 181, which makes ultrafiltration a good method for removing endotoxins 
from low molecular weight compounds. However, this method is inefficient for 
endotoxins removal from protein samples due to their relatively similar sizes. With 
ion exchange chromatography, it is only effective to remove endotoxins from 
positively charged proteins since endotoxins are normally negatively charged due to 
the phosphate groups 182. However, positively charged proteins and negatively 
charged endotoxins may form complexes which can reduce the overall efficiency of 
endotoxin removal. Polymyxin B affinity chromatography can also be utilized for 
removing endotoxins since polymyxin B, a peptide antibiotic, has a very high affinity 
toward the lipid A moiety of most endotoxins. Methods for endotoxin removal have 
been reviewed in some detail recently 178.  
Currently, the most used test for endotoxin levels is the Limulus Amebocyte 
Lysate (LAL) assay, also known as the Bacterial Endotoxin Test, and the endotoxin 
limits are expressed as EU (endotoxin units) 183. In preclinical research using animal 
models, the endotoxin limit is derived from human dose of 5 EU per kg and the 
maximum endotoxin level considered safe for a 30-g mouse is 0.15 EU administered 
over a 1-hour period 184. 
  
2.2.7 Preparation of recombinant rat TrxR1 
As mentioned earlier, the heterologous selenoprotein expression in E. coli 
inevitably results in a mixture of two forms of the target protein, a full length Sec 
containing selenoprotein and a UGA-truncated protein. For TrxR1, the truncated 
version (tTrxR1) is devoid of Sec-dependent enzymatic activity and the specific 
activity solely dependent on full length version (FL-TrxR1) of the recombinant TrxR1 
becomes decreased. In Paper IV, rat TrxR1 prepared for crystallization was purified 
through two affinity chromatography (i.e. 2’, 5’-ADP sepharose and PAO sepharose), 
of which 2’, 5’-ADP sepharose was used to pull down both tTrxR1 and FL-TrxR1 from 
the crude bacterial lysate while PAO sepharose was used to remove tTrxR1 from the 
FL-TrxR1. A typical purification process could increase the specific activity of TrxR1 
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from 15-20 U/mg prior to PAO sepharose purification to 40-50 U/mg afterwards. For a 
very long time we believed that this preparation of TrxR1 with around 40 U/mg 
specific activity should be mainly existed as the full length form, because the specific 
activity of wild type TrxR1 obtained from direct purification from rat liver was 
reported to be around 35 U/mg 185. However, our recent mass spectrometry analysis on 
different batches of TrxR1 has surprisingly shown that even for a TrxR1 preparation 
having a specific activity as high as 53 U/mg, only about 65% of the total area of all 
peaks detected are designated to FL-TrxR1 (Figure 14) 130. In this paper we also 
suggested that, theoretically, rat TrxR1 with full Sec content should have a specific 
activity of 70-80 U/mg.  
 
 
Figure 14. Mass spectrometry analysis of Sec-enriched TrxR1 from PAO 
Sepharose purification 130. TrxR1 was denatured using 50% acetonitrile and analyzed 
with TOFMS and the deconvoluted zero-charged ions (average mass) are shown. 
Peaks of 54,670±2 Da correlate with the theoretical mass of FL-TrxR1(54,671 Da) and 
peaks of 54,464±2 Da correlate with the theoretical mass of tTrxR1 (54,646 Da). Peaks 
of 55,250±2 Da correspond to tTrxR1 with bound FAD and peaks of 55,454±2 Da 
correspond to FL-TrxR1 with bound FAD.  
 
Another issue particularly important for recombinant TrxR1 preparation is the 
contamination from endogenous E. coli glutathione reductase (GR). Like mammalian 
TrxR1, GR also belongs to the family of homodimeric pyridine nucleotide-disulfide 
oxidoreductases and can bind to 2’5’-ADP sepharose specifically. As a result, the E. 
coli GR is often co-purified with recombinant TrxR1 after the 2’5’-ADP sepharose 
purification. For most studies on TrxR, this trace amount of contamination of GR is 
acceptable, but for some enzymatic studies, especially involved with the Grx system, 
this GR contamination could become crucial. For that reason it is important to remove 
E. coli GR. We currently employ two approaches to solve this problem. One is to 
include PAO sepharose purification in the TrxR1 preparation procedure since GR has 
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no affinity to this column, and the other is to use a special GR-deficient BL21 (DE3) 
gorˉ E. coli strain for rat TrxR1 production. 
 
2.2.8 Electron spin resonance 
In this thesis, particularly in Paper V, electron spin resonance (ESR) 
spectroscopy was intensively used to study the inherent NADPH oxidase activity of 
mammalian TrxR1.  
ESR is a technique for studying chemical species that have unpaired electrons, 
such as organic and inorganic free radicals. Unlike NMR detecting the excited spins of 
atomic nuclei, ESR detects excited electron spins instead. Although both techniques 
share similar physical concepts, ESR is less widely used than NMR because most 
stable molecules don’t possess unpaired electrons. However, this also means that the 
ESR technique is extremely specific, since there won’t be any background ESR spectra 
from the ordinary chemical solvents and matrixes. 
Since radicals are very reactive and short lived, normally they do not occur in 
high concentrations in biological environments. Specialized chemicals called spin 
trapping reagents are used for ESR measurements by extending the lifetime of the 
radicals via formation of spin adducts that yield unique ESR spectra (figure 15). In 
Paper V, several spin trapping reagents were used, including 5-diethoxyphosphoryl-5-
methyl-1-pyrroline-N-oxide (DEPMPO) and α-phenyl-N-tert-butylnitrone (PBN). 
 
Figure 15. Radical detection by ESR. DEPMPO is one of the most common spin 
trapping reagents for detection of superoxide and hydroxyl radical. Both radicals can 
attack DEPMPO to form the DEPMPO adducts, which have a longer half life and yield 
unique spectra under ESR study.   
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2.3 Results and discussion 
 
2.3.1 Paper I 
 
Selenolthiol and dithiol C-terminal tetrapeptide motifs for one-step purification 
and labeling of recombinant proteins produced in E. coli.  
 
(Scheme: Illustration of dithiol and selenolthiol tag applications) 
 
As previously described, we have shown that a redox-active Sec-containing 
tetrapeptide Sel-tag (Gly-Cys-Sec-Gly) can be used as a fusion motif for recombinant 
proteins produced in E. coli. 
Here, we have further developed the Sel-tag motif based on prior results of using 
mutants of Drosophila melanogaster TrxR. That enzyme has a cysteine residue in place 
of selenocysteine which is activated by flanking serine residues 186. Thus, we have 
produced recombinant Fel d 1 187, the major cat allergen from the domestic cat (Felis 
domesticus), with two dithiol (-GCCG and -SCCS) and two selenolthiol (-GCUG and -
SCUS) C-terminal tags. We subsequently assessed the use of these tags in one step 
purification, fluorescent labeling, and positron emitter labeling.  
PAO sepharose could be utilized to efficiently purify all four Fel d 1 variants 
from whole bacterial lysates in a single purification step yielding apparently 
homogeneous protein as judged by coomassie-stained SDS-PAGE analysis. The yield 
was about 5-10 mg pure protein from 1 liter bacterial culture. We next found that all 
tags could be fluorescent labeled with 5-IAF, with -GCCG being the least reactive and -
SCUS being the easiest to label. We finally assessed the use of both the selenolthiol and 
dithiol tags for selective labeling with a positron emitter typically used for positron 
emission tomography (PET) studies. For this, [11C]CH3I was utilized. Similar to the 
fluorescent labeling, both the selenolthiol and dithiol variants could be radiolabeled 
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with carbon-11. The labeling efficiencies of the selenolthiol motifs were, however, 
about 2~3-fold higher than the dithiol variants. In addition, only the selenolthiol tags 
can be labeled with selenium-75 through the in situ metabolic labeling.  
In summary, these results illustrate that the use of a Sel-tag or derivatives thereof 
for purification and residue-specific radiolabeling constitutes a promising technique for 
a wide range of novel protein-based applications mostly based upon Sec targeting with 
electrophilic compounds. 
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2.3.2 Paper II 
 
Prolonged antigen-exposure with carbohydrate particle based vaccination 
prevents allergic immune responses in sensitized mice  
 
(Figure: Whole-body autoradiography tracking of [75Se]rFel d 1)  
 
Mice are widely used for in vivo models of allergy and, in most cases, a 
functional animal model has to be established individually for each and every allergen 
due to the lack of a standard method to be applied. In this study, we have developed a 
mouse model for studying the major cat allergen Fel d 1187 and part of the goal is to use 
selenium-75 labeled Sel-tagged Fel d 1 in this animal model in order to detect and track 
the allergen in vivo. This was an approach previously demonstrated successfully for 
another allergen, Der p 2 188.  
To mimic pathogens and enable effective phagocytosis and antigen presentation, 
a small adjuvant is often used. In this study, we have utilized a novel carbohydrate 
based particle (CBP), sized 2 µm, as an adjuvant to be coupled with recombinant Fel d 
1 (rFel d 1). The vaccination with coupled CBP-rFel d 1 in rFel d 1-sensitized mice 
after allergen challenge prevented eosinophilic infiltration and airway inflammation. 
We have also observed that CBP-rFel d 1 vaccination could induce rapid antibody 
production even after just one injection, compared to either non coupled rFel d 1, CBP 
alone, or a simple mixture of both. This rapid induction of allergen-specific IgG 
suggests a potentially efficient treatment using CBP for allergy.  
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Utilizing FITC-labeled CBP, we found the CBP remained at the injection site at 
least 5 days after subcutaneous administration, which suggested that it would be 
possible to use CBP coupled allergen to extend the antigen presentation time. Whole-
body autoradiography using 75Se-labeled rFel d 1 coupled with and without CBP has 
substantiated this hypothesis. Briefly, we have performed an in vivo tracking of 100 µg 
[75Se]rFel d 1 (2 µCi) that was either coupled to CBP or adsorbed to aluminum 
hydroxide (alum). These two types of allergen complexes were subcutaneously injected 
into the four model mice (2 for each allergen complex) respectively. Twenty-four hours 
or one week after the injection, the mice were sacrificed and frozen for tape sectioning 
(60 µm thick). The sections were subsequently placed on X-ray film for 
autoradiography.  
The radioactivity in mice receiving [75Se]rFel d 1 adsorbed to alum was spread 
throughout the animals after 24 hours and remained detectable after 1 week. However, 
the radioactivity in CBP-[75Se]rFel d 1 immunized mice was located almost entirely at 
the injection site after 24 hours and the injection site was still detectable 1 week after  
the injection.  
We believe these observations have further strengthened the concept that CBP 
could be utilized to improve antigen-depot effects and therefore become a good 
adjuvant candidate for allergy vaccination both in a prophylactic and therapeutic 
perspective.  
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2.3.3 Paper III 
 
Multimodality imaging of Apoptosis through Sel-tagged Annexin A5 
 
(Figure: Sequential PET imaging of xenograft tumor in the same mouse using A: [11C]-AnxA5 
and B: [18F]FDG. Tumor is indicated by arrow) 
 
Annexin A5 is a member of the annexin family that share the property of Ca2+-
dependent binding to negatively charged phospholipids 189. Programmed cell death 
(PCD), or apoptosis, is characterized by a series of morphological and biochemical 
changes, including exposure of negatively charged phosphatidylserine (PS) on the cell 
surface 190; 191; 192. Through its binding with PS, annexin A5 has been successfully used 
to detect apoptotic cells both in vitro and in vivo 193. In this study, we have equipped 
annexin A5 with the Sel-tag and subsequently labeled this protein through the Sel-tag 
with either fluorescent 5-IAF or [11C]methyl iodide. The fluorescent- or radio-labeled 
annexin A5 retains its functionality for specific binding to apoptotic cells and proved to 
be useful in either fluorescent imaging or PET imaging. 
Using 5-IAF labeled Sel-tagged annexin A5, we are able to image either 
apoptotic or necrotic HeLa cells induced by the treatment of cisplatin. We could 
identify, through flow cytometry analysis, myeloma cells undergoing cell death treated 
with Velcade®. These results show that fluorescently labeled Sel-tagged annexin A5 
maintains functional binding to apoptotic cells.  
Carbon-11 is one of the most important positron emitters for PET studies, yet due 
to its fairly short half life, it is very difficult to perform in vivo PET imaging of a 
protein probe using carbon-11 as the positron emitter. In this study, we have further 
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optimized the protocol for protein radiolabeling with [11C]CH3I through the Sel-tag (see 
Materials and Methods section in the paper). The tracer preparation takes about 45 
minutes from the end of cyclotron bombardment to the end of synthesis and the 
radioactive conversion from [11C]CH3I to [11C]-AnxA5 is about 10-20% (decay-
corrected). HPLC analysis demonstrated the tracer was sufficiently radiochemically 
pure for in vivo studies. Due to the short half-life of carbon-11, we were able to perform 
two consecutive PET imaging in the same animal in the same day, including two 
sequential [11C]-AnxA5 in studies of liver apoptosis or two different tracers (i.e [11C]-
AnxA5 and  [18F]FDG, in tumor-bearing mice). 
Using [11C]-AnxA5, we imaged massive liver apoptosis induced by anti-FAS 
mAb in mice through two different experimental procedures. In the first one, two mice 
were intravenously injected with 10 µg anti-FAS mAb for 2 or 3 hours. [11C]-AnxA5 
was then intravenously injected followed by an immediate one-hour PET scanning. In 
untreated mice, the majority of the radioactivity was in the kidney and bladder by the 
end of a 60 min scan, showing extensive urinary elimination. In contrast, in the treated 
mice radioactivity accumulated in the livers and showed increased exposure to the anti-
FAS mAb. In another experiment, two consecutive PET scans were performed in the 
same animal, prior to and after the 10 µg anti-FAS mAb treatment respectively, 
enabling each animal to be its own control. A marked increase of the radioactivity 
uptake in the mouse liver was observed after the antibody treatment and the 
pharmacokinetics is clearly different.   
In a tumor PET imaging model, the xenograft tumors developed from FaDu cells 
could also be visualized with both [11C]-AnxA5 and [18F]FDG. The pharmacokinetics, 
however, was different for the two tracers. The ex vivo analysis by phosphorimaging of 
the excised tumor was performed immediately following the FDG scan and the higher 
resolution phosphorimaging was in line with the rather homogeneous distribution of 
radioactivity observed within the tumor in the PET images. Studies are continuing in 
the usefulness of [11C]-AnxA5 to monitor responses to chemotherapeutic agents in 
vivo. 
To conclude, we believe that the Sel-tag concept can be applied in broad aspects 
of molecular imaging based upon the utilization of protein probes. With the selenium-
dependent chemical features of the Sel-tag, it becomes possible to use proteins as 
efficient probes for functional imaging using PET as well as many other imaging 
applications.  
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2.3.4 Paper IV 
 
Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1 
 
(Figure: 2Fo-Fc electron density map showing the model of rat TrxR1 C-terminal active site in 
either oxidized selenolthiol (A) or reduced  selenenylsulfide (B) form.) 
 
Prior to this paper, several structural studies on mammalian TrxR have been 
published. However, none of these studies were able to use the wild type Sec 
containing enzyme that we have utilized here. This is mainly due to the limited 
availability of this pure selenoenzyme.   
In this study, we have used more than 200 mg of rat TrxR1 having a specific 
activity of at least 40 U/mg for numerous crystallization attempts. Crystals with 
reasonable resolution were obtained in the presence of 10 mM NADP+ from a solution 
of 15% PEG3350, 12% ethylene glycol, and 0.1 M HEPES, pH 7.5. The final models 
of TxR1 had a good geometry and consisted of 3 dimers with a high quality electron 
density map. The last six residues, where the Sec was located, appeared to be very 
flexible as we expected. However, weak electron density for the C-terminal motif was 
observed for three subunits. This allows us to define the general direction of the chain 
and, most importantly, we could determine the position and the structure of the 
selenenylsulfide motif in the oxidized enzyme at 3.1 Å resolution (PDB code 3EAO). 
The structure of the reduced enzyme containing a selenolthiol motif was also 
determined at a resolution of  2.75 Å (PDB code 3EAN), although the modeling is 
slightly poorer than the oxidized form. We also believe the reduced selenolthiol motif 
in the 2.75 Å structure was due to radiolysis.  
Surprisingly, the C-terminal oxidized selenenylsulfide motif was located far from 
the N-terminal redox active site, where it is believed to be the electron donor for the C-
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terminal active site. The selenium of Sec-498 in the selenenylsulfide bond was packed 
against the Tyr-116 phenol ring. However, in the reduced state it turned toward solvent 
and the presumed Trx-binding site of the enzyme, whereas the sulfur of Cys-497 
retained a position below the Tyr-116 ring. Based upon this structural information, we 
have proposed that the TrxR1-Trx intermediary complex exists in a mixed 
selenenylsulfide between Cys-32 of Trx and Sec-498 of TrxR1, which could readily be 
built with only very minor shifts in the active site cleft upon regularization. Upon 
interaction between the N-terminal active site, our model suggested that a 
selenenylsulfide intermediate between Sec-498 and Cys-59 was formed during the 
reduction of the C-terminal active site. However, we are well aware that the flexible C-
terminal could also allow modeling a Cys-497 to Cys-59 disulfide intermediate.  
Tyr-116 became an interesting target for this study due to its close position to the 
C-terminal active site. We therefore constructed three mutants, i.e. Y116F, Y116I, and 
Y116T. The Y116F was not soluble while Y116I and Y116T were obtained in high 
yields. All the enzymes including wt TrxR1 and the two Y116 mutants were purified as 
Sec-enriched proteins through PAO sepharose. For all the substrates we used, including 
DTNB, selenite, Juglone, lipoamide and Trx, both Y116I and Y116T were catalytically 
active with a lower enzymatic efficiency as indicated by their lower kcat/Km ratio for all 
the substrates tested herein compared with wild type enzyme. However Y116I 
displayed a surprisingly 7-fold elevated turnover utilizing juglone as substrate than with 
wild type TrxR1, which suggested that Tyr-116 mutations may not only affect the 
catalytic efficacy of TrxR1 but also potentially divert electron flow to advantage for 
some substrates, such as juglone. Briefly, we believe that the substitution of Try-116 
has diminished the attack on Sec-498 of the selenylsulfide from Cys-59. Thus the C-
terminal is left in the inactive oxidized state, while the N-terminal active site is 
preferably in its active conformation containing a reactive Cys-59 thiolate and a charge 
transfer complex between FAD and Cys-64. These are thereby available for other types 
of reactions, including one- (or two-) electron reduction of quinones such as juglone.  
Based on the structural and kinetic data, we have proposed a model to explain the 
catalysis of mammalian TrxR1 and the effects of Tyr-116. Although we believe this 
model is the most plausible given our current knowledge of this enzyme and it is in 
agreement with many prior studies, we are well aware that the model should be 
corroborated by future studies and may need to be revised. 
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2.3.5 Paper V 
 
The selenium-independent inherent pro-oxidant NADPH oxidase activity of 
mammalian TrxR and its selenium-dependent direct peroxidase activities.  
 
(Scheme: Inherent NADPH oxidase activity of TrxR1 and source of the resulting ESR findings.) 
 
As a key component of the thioredoxin (Trx) system, mammalian thioredoxin 
reductase (TrxR) is a Sec-containing flavoenzyme that has disulfide reductase activity 
using Trx as the principal substrate. The antioxidant functions of TrxR/Trx are widely 
accepted. However, TrxR may also have pro-oxidant properties especially upon redox 
cycling with certain low molecular weight substrates such as 2, 4-DNCB, curcumin, 
and juglone. Here, we studied these effects in more detail using novel rat TrxR1 
mutants and Electron Spin Resonance (ESR) with 5-diethoxyphosphoryl-5-methyl-1-
pyrroline-N-oxide (DEPMPO) as the spin trapping agent. In principle, the large amount 
of TrxR catalyzed O2˙ˉ generation stimulated by the agents mentioned above could be 
detected by the adrenochrome or cytochrome c methods. However, these methods are 
not sensitive enough to detect small amounts of O2˙ˉ. ESR with DEPMPO is ~20-fold 
more sensitive than the cytochrome c method for detection of O2˙ˉ, which allowed us to 
examine the significant inherent NADPH oxidase activity of mammalian TrxR in the 
absence of certain redox cycling agents. Also, as described earlier, mammalian TrxR is 
an enzyme containing multiple active sites. Therefore to clarify the contribution of 
TrxR catalyzed O2˙ˉ generation from these different active sites, we have used wild 
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type rat TrxR1 as well as its seven mutants in this study, which includes three 
previously established mutants, i.e. Y116I, Y116T (Paper IV) and a truncated mutant 
that is missing Sec-498 and Gly-499 194, and four new TrxR1 mutants, namely three 
single mutants (C59S, C64S, and U498C) and a double mutant (C59S/C64S).  
TrxR clearly exhibited enhanced NADPH oxidase activity and could generate 
free radicals including both hydroxyl radicals (HO˙) and superoxide (O2˙ˉ) upon 
NADPH reduction in the absence of other substrates. For example, 20 µM selenite 
decreased the ESR signal by 55% and 5 µM Trx together with 100 µM insulin decrease 
the ESR signal by 56%. The most likely explanation is that electron flow is more 
preferably channeled to these substrates instead of reacting with O2.  
SOD (Superoxide dismutase) and its mimetic MnTBAP (manganese (III) tetrakis 
(4-benzoic acid) porphyrin chloride) could eliminate both DEPMPO/HOO˙ and 
DEPMPO/HO˙ signals, indicating the O2˙ˉ is required for the generation of  the 
DEPMPO/HO˙ adduct by TrxR. Typical HO˙ generation is through the one-electron 
reduction of H2O2 by certain metals such as in the Fenton reaction. However the study 
had shown that free H2O2 was not required for HO˙ generation by TrxR.  
In this study, we also tried several classic inhibitors of TrxR, including auranofin, 
cisplatin, and 2, 4-DNCB to investigate their potential effects on the enzyme behavior 
in term of free radical generation. Auranofin (4 µM) only decreased the DEPMPO/HO˙ 
adduct signal by 28% although >99% DTNB-based TrxR activity was lost. Cisplatin 
(0.1 mM) did not affect the ESR signal much, implying that TrxR still generates 
DEPMPO/HO˙ when cisplatin is bound to the enzyme, which agrees with previous 
reports of cisplatin-derivatized TrxR in the form of SecTRAPs (selenium-compromised 
thioredoxin reductase-derived apoptotic protein) 194. 2, 4-DNCB dramatically changed 
the ESR spectra, with DEPMPO/HO˙ decreased by 46% and DEPMPO/HOO˙ 
increased by 11-fold. The increase in O2˙– reflects the previously reported induction of 
NADPH oxidase activity by 2, 4-DNCB, with most of the O2˙– generated by redox 
cycling of the nitro group of 2, 4-DNCB 93.  
Closer analyses using different mutants had revealed that the DEPMPO/HOO˙ˉ 
adduct was a direct substrate of TrxR that could be reduced to DEPMPO/HO˙ˉ in a 
Sec-dependent manner. The O2˙ˉ production itself, however, was Sec independent.  
All in all, the results presented in this paper probed the details of the catalytic 
cycle and reductive capacity of TrxR and may have relevance for the diverse reactions 
catalyzed by TrxR1 within the cellular context.   
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3 CONCLUSION 
 
The major conclusions from each individual paper were as follows: 
 
Paper I: Both dithiol and selenolthiol tetrapeptide tags can be used for efficient 
recombinant proteins purification over PAO sepharose. However, the 
selenolthiol variants were highly reactive in rapid labeling with 
electrophilic compounds including positron emitter such as [11C]CH3I. In 
addition, the selenolthiol variants also permit methodologically simple in 
situ 75Se-radiolabeling through the incorporation of [75Se]Sec. 
   
Paper II: 
 
 
 
The major cat allergen Fel d 1 was radiolabeled with γ-emitting selenium-
75 through a Sel-tag and subsequently used in an in vivo mouse model in 
order to track this protein allergen through a whole body autoradiography. 
From an immunology point of view, the paper has demonstrated that CBP 
is a potential adjuvant for use in allergy vaccination. 
 
Paper III: By equipping a recombinant protein with a novel multifunctional Sel-tag, 
this opens several new possibilities for purification as well as functional 
multimodality imaging, including visualization of apoptosis using either 
fluorescent- or radio- labeled Sel-tagged annexin A5. 
 
Paper IV: 
 
The structural characteristics of the unique selenenylsulfide/selenolthiol 
motif of rat TrxR1 were illustrated and a detailed model for its 
involvement in the enzymatic catalysis, invoking a key role for the 
aromatic ring of Tyr-116 was proposed.  
 
Paper V: Upon NADPH reduction, TrxR1 could generate free radicals resulting in 
predominant DEPMPO/HO˙ and some DEPMPO/HOO˙. However, 
DEPMPO/HO˙ formation is dependent upon O2˙ˉ generation due to a 
Sec-independent NADPH oxidase activity and subsequent Sec-dependant 
peroxidase-like activity of TrxR reducing DEPMPO/HOO˙ to 
DEPMPO/HO˙ˉ.  
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4 FUTURE PERSPECTIVES 
4.1 Recombinant selenoprotein production 
Since the first selenoprotein was discovered in 1973, new types of selenoproteins 
have been continuously identified. In recent years, the in silico genomics approaches to 
look for selenoprotein genes based upon searching the unique features of selenoprotein 
biosynthesis machineries have greatly increased our knowledge about the distribution 
of selenoproteins among different organisms. It is generally believed that Sec often 
serves as a catalyst in redox reactions by selenoprotein. However, due to the distinct 
barriers of selenoprotein synthesis machineries across different species, it is difficult to 
study these selenoproteins in their wild type Sec-containing form using conventional 
recombinant protein expression system, especially in E. coli as the suppliers of 
selenoproteins. However, for recombinant expression of certain types of selenoproteins, 
namely the proteins containing a C-terminal Sec residue, it is possible to utilize the 
method we employed in this thesis. For other selenoproteins containing internal or 
multiple Sec, technical barriers remain to this day. Other methods had been utilized to 
express selenoprotein, such as native chemical ligation 195, recombinant expression in 
mammalian cells 196, or intein based selenoprotein production 197; 198. However, all of 
these methods are neither efficient, nor applicable for production of most 
selenoproteins.  
We have also proposed two approaches for the recombinant expression of 
selenoproteins containing internal Sec, both are based upon our previous studies of 
herterologous selenoprotein expression in E. coli.  
In the first approach, we attempt to utilize an intein methodology, which has a 
different perspective from the previous method. Briefly, intein is a protein segment that 
is able to excise itself from its parent protein and rejoin the remaining two polypeptides 
(N-extein and C-extein respectively) with a peptide bond. In our case, the Sec will be 
positioned at the C-terminal of N-extein, while the amino sequence derived from 
SECIS element will be placed in the N-terminal intein. The self removal of intein will 
result in a complete selenoprotein without traces of the SECIS element. The biggest 
challenge is to find a suitable SECIS element that is dual-functional. On one hand it 
should be recognized by the bacterial Sec-specific elongation factor SelB to ensure the 
Sec incorporation, and on the other hand the mutation inevitably introduced into the 
engineered intein motif from the SECIS element should not affect its splicing function.  
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The second one is a directed-evolutionary approach and it still largely remains at 
a theoretical level. As mentioned earlier, the bacterial Sec-specific elongation factor 
SelB is composed of two domains, SelB-N and SelB-C. Of these SelB-N is 
homologous to EF-Tu, which specifically recruits Sec-tRNASec and delivers Sec into 
the growing polypeptide, while the SelB-C is responsible for recognizing the SECIS 
element. From structural studies, these two domains are relatively independent to each 
other. Thereby we hypothesized if we can randomly mutate the SelB-C domain, 
especially at the region for SECIS recognition, we might be able to obtain some Sel-B 
mutants that could recognize a given sequence (ultimately any given sequence) other 
than the wild type SECIS as a novel “SECIS” element. To achieve this, a powerful 
selection method must be employed simultaneously. 
We believe both approaches are not trivial and the development of a proof-of-
principle is certainly needed. 
 
4.2 Biotechnological application based upon selenoprotein 
As a proof of principle, we have already shown that we can use Sel-tag for 
specific protein labeling and subsequently utilize the labeled protein for different 
applications, such as an in vivo tracking of the protein allergen Fel d 1 in a mouse 
allergen model (Paper II) and multimodality imaging of apoptosis through Sel-tagged 
annexin A5 (Paper III). Ultimately, the major goal of utilizing Sel-tag is to develop 
and apply new technology for functional tumor imaging based upon selective and 
specific radiolabeling of protein probes through the Sel-tag. Currently, we are 
developing this concept in three different directions. 
 
I.  PET imaging of apoptosis 
We are continuously developing the use of Sel-tagged annexin A5 in tumor 
imaging through PET. We wish to use this protein to assess the extent of apoptosis in 
mouse models of treated cancer (xenograft tumor model with treatment using 
conventional and novel chemotherapeutic drugs). The already demonstrated ability of 
the labeled protein to reveal the timing and degree of chemotherapeutic effects has a 
high potential for translation to the PET imaging of patients. Correlation of in vivo 
apoptosis detection with the appearance of blood markers will provide a solid ground 
for novel strategies for detecting and optimizing therapeutic responses.  
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II. PET imaging of angiogenesis 
Angiomotin is expressed in the endothelium of newly forming vessels, the 
inhibition of which prevents angiogenesis as shown using animal models. In this 
project, we have constructed a Sel-tagged scFv (single-chain antibody fragments) 
against angiomotin, which will be used to perform in vivo angiogenesis imaging in a 
tumor model.  These scFv molecules are derived from the same clone as that inhibiting 
angiogenesis in vivo, whereby the biodistribution and pharmacokinetics of the scFv can 
be evaluated using PET. With the goal of utilizing these technologies for the validation 
of ongoing angiogenesis as a means of diagnosis of solid tumor formation in vivo, we 
expect that the development of Sel-tagged scFv based projects to have major clinical 
and pharmaceutical value for therapy validation. Moreover, a possibility exists based 
upon this project for the development of new functional imaging for assessment of anti-
angiogenic or anti-cancer therapy, based upon the in vivo imaging of angiogenesis and 
the termination of such processes by pharmaceutical treatment.  
 
III. High-affinity binding molecules for specific cancer detection 
To detect specific types of cancer cells by PET imaging, a cell type-specific PET 
tracer that can bind with high affinity and high specificity to unique cancer cell surface 
is needed. For this purpose, a unique type of small polypeptides named affibody will be 
utilized under the Sel-tag concept. Affibody molecules are generated from the Z-
domain, a protein scaffold used in combinatorial library selections derived from 
staphylococcal protein A. Affibody molecules are relatively small (~6 kDa) and highly 
stable, they can be expressed in E. coli with high solubility, and most selected affibody 
molecules have no Cys residues. All these properties make affibody an optimal 
candidate for protein labeling through a Sel-tag. As a pilot study, we have chosen an 
affibody that has been shown to target human epidermal growth factor receptor 2 
(HER2) overexpressed in breast cancer cells. Our earlier studies have already shown 
that the Sel-tagged affibodyHER2 can be labeled with either fluorescent 5-IAF or 
positron-emitting [11C]CH3I. We are currently constructing a follow-up mouse model to 
apply this protein tracer for PET imaging of breast cancer. Moreover, several other 
affibody molecules with different cancer cell targets are also under development.  
All together, we believe that the Sel-tag technique provides great opportunities  
for the development of proteins as biomarkers for non-invasive functional imaging, 
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especially PET imaging, which eventually might prove useful for cancer research as 
well as clinical practice.   
 
4.3 Mammalian thioredoxin reductase 
As one of the most important antioxidant enzymes, research potential around 
mammalian TrxR is tremendous and there are still so many puzzles about this enzyme 
and related proteins yet to be solved.  
In Paper IV, we have solved the structure of rat TrxR1 as a native Sec-
containing protein. Based on the structural data and the kinetics of several TrxR1 
mutants, we have proposed a model to explain the catalysis by TrxR1. The fact that we 
are able to determine the crystal structure of a recombinant selenoprotein sheds light on 
possibilities to produce additional Sec-containing selenoproteins similar to TrxR1 
studied herein for further detailed molecular and structural studies.  
In a recently published paper, we have identified a stable tetrameric form of Sec-
containing rat TrxR1 130. In order to understand the conformation as well as the 
potential physiological impact of this tetrameric TrxR1, we have recently crystallized 
this unique TrxR1 form and an in-depth study on its structure and several 
corresponding mutants are currently being carried out.  
In Paper V, we have revealed that TrxR1 had an inherent NADPH oxidase 
activity that can surprisingly catalyze a significant superoxide production, which is in 
line with the previously described induction of TrxR1 NADPH oxidase activity by 
certain low molecular compounds. Redox cycling of these low molecular compounds 
catalyzed by the N-terminal active site of TrxR1 seems to play a major role in such 
NADPH oxidase activity. In a current follow-up study, utilizing ESR, we have 
intensively investigated the interaction between TrxR and certain quinones to 
understand which of its redox centers are responsible for quinone reduction.  
It has been widely accepted in recent years that TrxR1 is a promising anticancer 
target. Therefore the discovery of novel compounds that could target TrxR1 are of 
importance for novel cancer drug development. We have recently submitted a paper 
describing a high throughput assay for simultaneous identification of inhibitor and 
substrates of TrxR1 in a single-enzyme, dual-purpose assay. We are now expanding 
this assay in screening a large chemical library containing more than two hundred 
thousand compounds. After the screening, the compounds with high scores will be 
further studied for characterization as either an inhibitor and/or a substrate of TrxR1.  
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